NCT00077181: 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies |
|
|
| Completed | 1 | 48 | US | cytarabine, ARA-C, arabinofuranosylcytosine, arabinosylcytosine, Cytosar-U, cytosine arabinoside, triapine, 3-AP, OCX-191, laboratory biomarker analysis | National Cancer Institute (NCI) | Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia | 07/08 | | | |
NCT00077558: 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome |
|
|
| Completed | 1 | | US | fludarabine phosphate, triapine | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI) | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases | | | | |